drugset
drugset / Trial / NCT03083990

Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male

NCT03083990 ↗

Phase 1 Completed 100 enrolled Innovent Biologics (Suzhou) Co. Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To confirm the PK similarity of IBI305 and bevacizumab in healthy volunteers .

Timeline

Start
2017-03-09
Primary completion
2017-08-17
Completion
2017-08-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bevacizumab Monoclonal antibody 3 mg/kg Other

Indications

No indication recorded.